Outpatient treatment with 2 cycles of Bendamustine, Gemcitabine and Dexamethasone is Effective and Safe in r/r Hodgkin Lymphoma—Polish Lymphoma Research Group Study.

Autor:	Paszkiewicz‐Kozik, E., Kurlapski, M., Swoboda, R., Subocz, E., Szymanski, M., Taszner, M., Wicherska‐Pawlowska, K., Koclega, A., Domanska‐Czyz, K., Swierkowska, M., Woszczyk, D., Targonski, L., Chmielowska, E., Dabrowska‐Iwanicka, A., Ostrowska, B., Romejko‐Jarosinska, J., Kotarska, M., Druzd‐Sitek, A., Konecki, R., Mroz‐Zycinska, E.
Předmět:	HODGKIN'S disease RESEARCH teams GEMCITABINE LYMPHOMAS DEXAMETHASONE
Zdroj:	Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p364-364, 1p
Abstrakt:	Infections occurred in 18% ( I n i = 20) of pts during 2 BGD, 24% ( I n i = 27) if treatment was extended, majority of them were GRADE <3. B Introduction: b BURGUND is a phase II study evaluating the combination of bendamustine, gemcitabine and dexamethasone (BGD) as the first salvage therapy in patients with refractory or relapsed Hodgkin lymphoma (r/r HL). Pts received 1 ( I n i = 3), 2 ( I n i = 58), 3 ( I n i = 28), or 4 ( I n i = 23) cycles of BGD. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text